35216-39-8

Usage

Uses

Used in Pharmaceutical Industry:
3-(METHYLSULFONYL)ANILINE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in the Preparation of Substituted Pyrazolopyrimidines:
3-(METHYLSULFONYL)ANILINE is used as a starting material for the preparation of substituted pyrazolopyrimidines, which are known as IRAK4 kinase inhibitors. These inhibitors play a crucial role in the regulation of inflammatory responses and have potential applications in the treatment of various inflammatory diseases and conditions.

InChI:InChI=1/C7H9NO2S/c1-11(9,10)7-4-2-3-6(8)5-7/h2-5H,8H2,1H3

Upstream product

• 1783-81-9 3-methylmercaptoaniline 
• 124-63-0 methanesulfonyl chloride 
• 626-01-7 3-Iodoaniline 
• 3112-85-4 methylphenylsulfonate 
• 20277-69-4 sodium methansulfinate 
• 591-19-5 m-Bromoaniline 
• 19614-16-5 2-bromo-1-(methylsulfanyl)benzene 
• 13257-95-9 3-nitrobenzenesulfinic acid 
• 3937-95-9 3-Nitrophenylsulfonylessigsaeure 
• 2976-32-1 1-methanesulfonyl-3-nitro-benzene 
• 33951-33-6 1-bromo-2-(methylsulfonyl)benzene 

Downstream Products

• 107516-85-8 (3-methanesulfonyl-phenyl)-phenyl-diazene 
• 125802-65-5 (9-Benzyl-2-chloro-9H-purin-6-yl)-(3-methanesulfonyl-phenyl)-amine 
• 54743-68-9 1-isothiocyanato-3-(methylsulfonyl)benzene 
• 522599-89-9 5-(4-chloro-phenyl)-7-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-2-carboxylic acid (3-methanesulfonyl-phenyl)-amide 
• 503182-92-1 4-[(3-methanesulfonylphenyl)hydrazono]-4H-pyrazole-3,5-diamine 
• 159177-51-2 3-(3-methanesulphonyl)phenyl-4-thiazolidinone 
• 1403818-72-3 N-(3-(methylsulfonyl)phenyl)-5-(thiophen-2-yl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1403818-94-9 5-(2-fluorophenyl)-N-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1403818-71-2 N,5-bis(3-(methylsulfonyl)phenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1366128-02-0 2,4-difluoro-N-[2-(methyloxy)-5-(2-({[4-(methyloxy)phenyl]methyl}amino)-3-{[3-(methylsulfonyl)phenyl]amino}-6-quinolinyl)-3-pyridinyl]benzenesulfonamide 
• 1254057-15-2 4-chloro-2-(methylsulfanyl)-6-{[3-(methylsulfonyl)phenyl]amino}pyrimidine-5-carboxamide 
• 1254049-66-5 6-ethyl-5-[(1-methylpiperidin-3-yl)amino]-3-{[3-(methylsulfonyl)phenyl]amino}pyrazine-2-carboxamide 
• 1254048-03-7 5-{[(1-aminocyclohexyl)methyl]amino}-6-ethyl-3-{[3-(methylsulfonyl)phenyl]amino}pyrazine-2-carboxamide 
• 1254057-16-3 2-(methylsulfanyl)-4-{[3-(methylsulfonyl)phenyl]amino}-6-oxo-1,6-dihydropyrimidine-5-carboxamide 

Relevant academic research and scientific papers

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Aromatic C-H amination in hexafluoroisopropanol

We report a direct radical aromatic amination reaction that provides unprotected anilines with an improvement in the substrate scope compared to prior art. Hydrogen bonding by the solvent hexafluoroisopropanol to anions of cationic species is responsible for increased reactivity and can rationalize the enhancement in substrate scope. Our findings may have bearings on radical additions to arenes for direct C-H functionalization in general.

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

A Class of Amide Ligands Enable Cu-Catalyzed Coupling of (Hetero)aryl Halides with Sulfinic Acid Salts under Mild Conditions

The amide derived from 4-hydroxy-l-proline and 2,6-dimethylaniline is a powerful ligand for Cu-catalyzed coupling of (hetero)aryl halides with sulfinic acid salts, allowing the formation of a wide range of (hetero)aryl sulfones from the corresponding (hetero)aryl halides at considerably low catalytic loadings. The coupling of (hetero)aryl iodides and sodium methanesulfinate proceeds at room temperature with only 0.5 mol % CuI and ligand, representing the first example for Cu-catalyzed arylation at both low catalytic loading and room temperature.

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE

Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.

ANTIVIRAL PYRIMIDINES

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS

The present invention provides compounds of formula (I): in which Y is oxygen or sulphur; R1 and R”1 are optionally substituted aryl, heteroaryl or a fused ring structure, R2and R'2 are each H, or optionally substituted alkyl, alkylaminoalkyl or dialkylaminoalkyl, or R2 and R'2 and their N form a saturated or unsaturated optionally substituted heterocycle, R3 represents a group of formula -(CH2)P-Ar-Rn, wherein p is 0 or 1 and, when p is 1, is optionally substituted, Ar is aryl or heteroaryl, and each R is H, halogen; hydroxyl; trifiuoromethyl; linear and branched alkyl, alkenyl, alkynyl, and alkoxyl groups, all optionally further substituted by one or more of hydroxy groups, halogen atoms, alkoxy groups, amino groups, and alkylthio groups; linear and branched alkoxyl groups; linear and branched thioalkyl groups; aryl groups; aralkyl groups; aralkoxy groups; aryloxy groups; perfluoroalkyl; -CN; -NR4R5, -C(=X)NR4R5,-O-C(=X)NR4R5, -SO2NR4R5, - Alk-NR4R5, -NZC(=X)(NH)qR6, -Alk-NZC(=X)(NH)qR6, -C(=X)R6, -Alk-C(=X)(NH)qR6, -NHSO2R7, -SO2R7, -SOR7, -SR7, or is a saturated or unsaturated heterocyclyl group, and salts and esters thereof, are useful in the treatment of conditions susceptible to modulating ion channels, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.

Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors

The introduction of 3-arylmethyl, 3-aryloxy and 3-arylthio moieties into a 6-methylsulfonylindole framework using rational drug design led to potent, selective COX-2 inhibitors having efficacy in a rat carrageenan air pouch model. Incorporation of a conformationally more rigid 3-aroyloxy substituent onto the 6-methylsulfonylindole scaffold led to selective, but considerably less potent COX-2 inhibitors. Variation of the hydrophilicity and size of the indole 2-substituent of 3-arylthio-6-methylsulfonylindole inhibitors led to modulation of the COX-2 human whole blood (HWB) potency and selectivity. The introduction of 3-arylmethyl, 3-aryloxy and 3-arylthio moieties into a 6-methylsulfonylindole framework using rational drug design led to potent, selective COX-2 inhibitors having efficacy in a rat carrageenan air pouch model. Incorporation of a conformationally more rigid 3-aroyloxy substituent onto the 6- methylsulfonylindole scaffold led to selective, but considerably less potent COX-2 inhibitors. Variation of the hydrophilicity and size of the indole 2-substituent of 3-arylthio-6-methylsulfonylindole inhibitors led to modulation of the COX-2 human whole blood (HWB) potency and selectivity.

Herbicidally active phenylsubstituted 5-and 6-membered heterocyclic compounds

A compound of formula (I): STR1 where E is oxygen or sulphur; A is CR3 or N where R3 is hydrogen or hydrocarbyl; D completes a 5 or 6-membered non-aromatic heterocyclic ring which optionally contains additional heteroatoms selected from oxygen, nitrogen or sulphur and which is optionally substituted by an optionally substituted lower hydrocarbyl group, or an optionally substituted heteroaryl group; R1 and R2 are each independently hydrogen; optionally substituted lower hydrocarbyl, or optionally substituted heteroaryl, or R1 and R2 together with the nitrogen atom to which they are attached, form a heterocyclic ring; Z represents halogen optionally substituted lower hydrocarbyl, optionally substituted lower hydocarbyloxy, optionally substituted lower hydrocarbylthio, hydrocarbylsulphinyl or hydrocarbylsulphonyl, cyano, nitro, CHO, NHOH, ONR7' R7", SF5 ; CO (optionally substituted lower hydrocarbyl), acylamino, COOR7, SO2 NR8 R9, CONR10 R11, OR12 or NR13 R14 where R7, R7', R7", R8, R9, R10 and R11 are independently hydrogen or lower hydrocarbyl; R12 is hydrogen; SO2 lower hydrocarbyl or COR15 ; R13 and R14 are independently lower hydrocarbyl, lower hydrocarbyloxy or a group R12 ; R15 is OR16, NR17 R18, hydrogen or lower hydrocarbyl; R16 is lower hydrocarbyl; R17 and R18 are independently hydrogen or lower hydrocarbyl; provided that when there are two or more substituents Z, they may be the same or different; and m is 0 or an integer from 1 to 5.